Primary hyperaldosteronism – the most common form of secondary hypertension

Česká verzia

Authors: B. Štrauch; J. Widimský jr.
Authors place of work: III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze, Centrum pro výzkum, diagnostiku a léčbu hypertenze
Published in the journal: Kardiol Rev Int Med 2015, 17(2): 155-160
Category: Internal Medicine

Summary

Primary aldosteronism is the most common form not only of endocrine, but also secondary hypertension, associated with increased cardiovascular risk. It is caused by autonomous overproduction of aldosterone by the adrenal cortex. Clinically, it manifests with hypertension often resistant to treatment and hypokalaemia. The screening tool is the increased ratio of aldosterone/ renin due to increased concentrations of aldosterone and low levels of renin, and the diag-nosis is confirmed by the lack of suppression of aldosterone during confirmatory tests. Before indication for surgical treatment, adrenal venous sampling is used in the majority of patients to assess lateralization. In other cases is indicated treatment with aldosterone receptor blockers is indicated. Given the complexity of the diagnostic process, patients with suspected PH should be treated only in specialized centres.

Keywords:
primary aldosteronism – hypertension – aldosterone – renin

Zdroje

1. Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253– 267.

2. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293– 2300. doi: 10.1016/ j.jacc.2006.07.059.

3. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349– 352. doi: 10.1038/ sj.jhh.1001554.

4. Carss KJ, Stowasser M, Gordon RD et al. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens 2011; 25: 560– 564. doi: 10.1038/ jhh.2010.93.

5. Zelinka T, Strauch B, Pecen L et al. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004; 18: 107– 111. doi: 10.1038/ sj.jhh.1001644

6. Zelinka T, Holaj R, Petrak O et al. Life‑ threatening arrhythmia caused by primary aldosteronism. Med Sci Monit 2009; 15: CS174– CS177.

7. Mulatero P, Stowasser M, Loh KC et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045– 1050. doi: 10.1210/ jc.2003‑ 031337.

8. Stehr CB, Mellado R, Ocaranza MP et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010; 28: 2120– 2126. doi: 10.1097/ HJH.0b013e32833d0177.

9. Rizzoni D, Paiardi S, Rodella L et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638– 2642. doi: 10.1210/ jc.2006‑ 0101.

10. Holaj R, Zelinka T, Wichterle D et al. Increased intima‑ media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451– 1457. doi: 10.1097/ HJH.0b013e3281268532.

11. Holaj R, Rosa J, Zelinka T et al. Long‑term effect of specific treatment of primary aldosteronism on carotid intima‑ media thickness. J Hypertens 2014; 33: 874– 882. doi: 10.1097/ HJH.0000000000000464.

12. Strauch B, Petrak O, Wichterle D et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909– 914. doi: 10.1016/ j.amjhyper.2006.02.002.

13. Strauch B, Petrak O, Zelinka T et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008; 21: 1086– 1092. doi: 10.1038/ ajh.2008.243.

14. Tsioufis C, Tsiachris D, Dimitriadis K et al. Myocardial and aortic stiffening in the early course of primary aldosteronism. Clin Cardiol 2008; 31: 431– 436. doi: 10.1002/ clc.20270.

15. Catena C, Colussi G, Lapenna R et al. Long‑term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911– 918. doi: 10.1161/ HYPERTENSIONAHA.107.095448.

16. Indra T, Holaj R, Strauch B et al. Long‑term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2014. In press. doi: 10.1177/ 1470320314549220.

17. Savard S, Amar L, Plouin PF et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross‑ sectional study. Hypertension 2013; 62: 331– 336. doi: 10.1161/ HYPERTENSIONAHA.113.01060.

18. Sindelka G, Widimsky J, Haas T et al. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000; 108: 21– 25.

19. Catena C, Lapenna R, Baroselli S et al. Insulin sensitivity in patients with primary aldosteronism: a follow‑up study. J Clin Endocrinol Metab 2006; 91: 3457– 3463. doi: 10.1210/ jc.2006‑ 0736.

20. Strauch B, Widimsky J, Sindelka G et al. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 2003; 52: 503– 506.

21. Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266– 3281. doi: 10.1210/ jc.2008‑ 0104.

22. Ahmed AH, Gordon RD, Taylor PJ et al. Effect of contraceptives on aldosterone/ renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96: 1797– 1804. doi: 10.1210/ jc.2010‑ 2918.

23. Ahmed AH, Calvird M, Gordon RD et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/ renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab 2011; 96: 1039– 1045. doi: 10.1210/ jc.2010‑ 2603.

24. Ahmed AH, Cowley D, Wolley M et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99: 2745– 2753. doi: 10.1210/ jc.2014‑ 1153.

25. Young WF, Stanson AW, Thompson GB et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227– 1235. doi: 10.1016/ j.surg.2004.06.051.

26. Rossi GP, Auchus RJ, Brown M et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63: 151– 160. doi: 10.1161/ HYPERTENSIONAHA.113.02097.

27. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2: 198– 208. doi: 10.1038/ ncpneph0151.

28. Citton M, Viel G, Rossi GP et al. Outcome of surgical treatment of primary aldosteronism. Langenbeck's Arch Surg 2015; 400: 325– 331. doi: 10.1007/ s00423‑ 014‑ 1269‑ 4.

29. Parthasarathy HK, Menard J, White WB et al. A double‑blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980– 990. doi: 10.1097/ HJH.0b013e3283455ca5.